开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

交易中 09-08 14:35:13

1.820

-0.065

-3.45%

最高1.890	最低1.800	成交量51.80万
今开1.885	昨收1.885	日振幅4.77%
总市值9.08亿	流通市值9.08亿	总股本4.99亿
成交额94.91万	换手率0.10%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":1.82,"timestamp":1788848870071,"preClose":1.885,"halted":0,"volume":518000,"delay":0,"changeRate":-0.03448275862068963,"floatShares":499000000,"shares":499000000,"eps":-0.5197889579200741,"marketStatus":"交易中","change":-0.065,"latestTime":"09-08 14:35:13","open":1.885,"high":1.89,"low":1.8,"amount":949145,"amplitude":0.047745,"askPrice":1.85,"askSize":4500,"bidPrice":1.82,"bidSize":5500,"shortable":0,"etf":0,"ttmEps":-0.4693961623138863,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1788855000000},"marketStatusCode":2,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":1.885,"openAndCloseTimeList":[[1788831000000,1788840000000],[1788843600000,1788854400000]],"volumeRatio":0.423835,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"1113703587","title":"港股生物医药股午后走强，剂泰科技-P涨近15%，百奥赛图-B、金斯瑞生物科技涨近10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113703587","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113703587?lang=zh_cn&edition=full","pubTime":"2026-09-08 13:33","pubTimestamp":1788845625,"startTime":"0","endTime":"0","summary":"9月8日，港股$生物(000504)$医药股午后走强，$剂泰科技-P(07666)$涨近15%，$百奥赛图-B(02315)$、$金斯瑞生物科技(01548)$涨近10%，$泰格医药(03347)$、$康希诺生物(06185)$、$云顶新耀(01952)$涨超5%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","XBI","399441","01952","BK1161","HK0000306685.HKD","BK1191","BK4588","BK1515","BK4581","161726","09939","BK1583","BK1576","HK0000320264.USD","VXUS","06185","688796","BK1574","01548","BK4585","03347","02315","BK0216","HK0000306701.USD","07666","KCAI","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665349337","title":"港股异动 | 礼邦医药-B(09637.HK)涨超6% 纳入港股通及恒生综合指数落地 美信罗销售同比增约105% 商业化兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2665349337","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665349337?lang=zh_cn&edition=full","pubTime":"2026-09-08 10:16","pubTimestamp":1788833785,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","HSCI","BK1191","BK1515","09637","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665342811","title":"9月8日议程｜科创出海，药启新程·2026上海国际医药健康创新与资本大会暨第15届医药CEO论坛","url":"https://stock-news.laohu8.com/highlight/detail?id=2665342811","media":"国泰君安证券研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665342811?lang=zh_cn&edition=full","pubTime":"2026-09-08 07:00","pubTimestamp":1788822000,"startTime":"0","endTime":"0","summary":"重要提醒本订阅号所载内容仅面向国泰海通证券研究服务签约客户。因本资料暂时无法设置访问限制，根据《证券期货投资者适当性管理办法》的要求，若您并非国泰海通证券研究服务签约客户，为保证服务质量、控制投资风险，还请取消关注，请勿订阅、接收或使用本订阅号中的任何信息。法律声明本公众订阅号为国泰海通证券股份有限公司 研究所依法设立、独立运营的唯一官方订阅号。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650541522&idx=2&sn=6c85823d61d83e5b4f1f3ec195ee0973&chksm=8986560c9678a453a9576a65ef4ade6c11e045b68559c766d99b17ed842f39765cf4a99b674b&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["09939","159982","159938","BK1574","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665312996","title":"大瓜！券商医药研究员转行看电子去了","url":"https://stock-news.laohu8.com/highlight/detail?id=2665312996","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665312996?lang=zh_cn&edition=full","pubTime":"2026-09-07 21:05","pubTimestamp":1788786300,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！（来源：花尔街之狼）券商医药研究员转行看电子去了本科硕士都学的医学，怎么转行看电子了？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-07/doc-iniqzhfu5386610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1515","159938","KCE","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319588","title":"曾被估价1.54亿元,如今2400万元挂牌 济南平嘉大药房60%股权再寻买家","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319588","media":"经济导报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319588?lang=zh_cn&edition=full","pubTime":"2026-09-07 18:08","pubTimestamp":1788775680,"startTime":"0","endTime":"0","summary":"目前,济南平嘉股东分别为天士力医药和董红兵,持股比例分别为60%和40%。此次挂牌转让的,正是天士力医药所持有的60%股权。此次挂牌之所以引发关注,一个重要原因在于济南平嘉60%股权此前曾以较高价格进入市场视野。当时的评估结果显示,以2023年3月31日为评估基准日,济南平嘉100%股权评估值为26071.26万元,评估增值率达到1099.54%。如今,两年多时间过去,济南平嘉60%股权再次被摆上产权交易市场,挂牌底价已经变为2400万元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-07/doc-iniqyzxs9592354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301017","09939","BK1161","BK1515","BK1574","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398982","title":"礼邦医药-B公布H股获纳入港股通及恒生综合指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398982","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665398982?lang=zh_cn&edition=full","pubTime":"2026-09-07 08:50","pubTimestamp":1788742200,"startTime":"0","endTime":"0","summary":"模拟交易客户端礼邦医药-B公布，据港股通的相关安排及调整，公司H股获纳入港股通合资格证券名单，将自2026年9月7日（星期一）起生效。H股获纳入港股通乃基于其获纳入恒生综合指数。董事会认为，H股获纳入港股通及恒生综合指数，反映了资本市场对公司价值及长期发展前景的认可，并将有助于进一步扩大公司的投资者基础，提升H股的交易流动性。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-09-07/doc-iniqyeua9585261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","09637","159938","HSCI","09939","FLHK","BK1515","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665601053","title":"开拓药业-B(09939.HK)：KT-939人体长期安全性试验顺利完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2665601053","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665601053?lang=zh_cn&edition=full","pubTime":"2026-09-07 08:01","pubTimestamp":1788739288,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1515","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665367071","title":"2026年国家医保谈判在北京启动；珍视明回应滴眼液抽检不合格事件 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2665367071","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665367071?lang=zh_cn&edition=full","pubTime":"2026-09-07 07:01","pubTimestamp":1788735712,"startTime":"0","endTime":"0","summary":"丨2026年9月7日星期一丨NO.12026年国家医保谈判在北京启动9月5日，2026年国家医保目录谈判竞价和商保创新药目录价格协商在北京启动，预计持续4至5天。新版目录有望于11月底前公布，2027年1月1日起执行。与往年相比，今年国谈整体提前约一个月，已有59个创新药完成参考药预沟通，并新增创新药“预申报”。点评：预沟通与预申报缩短创新药准入周期，有利于药企加快商业化节奏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866183218.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866183218.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BMED","09939","XLVI","BK1161","159938","APXH","BK1574","BK1515","PBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188805091","title":"开拓药业-B（09939）宣布KT-939完成52周人体长期安全性试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1188805091","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188805091?lang=zh_cn&edition=full","pubTime":"2026-09-07 06:11","pubTimestamp":1788732676,"startTime":"0","endTime":"0","summary":"2026年9月7日，开拓药业-B发布自愿公告称，公司自主研发的抑制黑色素生成的新型高效酪氨酸酶抑制剂KT-939已于2026年9月4日完成为期52周的人体长期安全性试验。该试验共纳入114位受试者，在连续52周外用0.2% KT-939后，初步数据显示未出现皮肤不良反应，且与2026年6月10日披露的28周中期结果一致。公司表示，将在获得本次试验结果后，加快推进KT-939向国家药品监督管理局的注册申报工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665627263","title":"股市必读：白云山新发布《广州白云山医药集团股份有限公司2026年半年度权益分派实施公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2665627263","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665627263?lang=zh_cn&edition=full","pubTime":"2026-09-07 01:15","pubTimestamp":1788714911,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，白云山报收于20.24元，上涨0.25%，换手率0.55%，成交量7.7万手，成交额1.56亿元。公司公告汇总：白云山将于2026年9月10日实施2026年半年度权益分派，每股派发现金红利0.30元（含税），共计派发487,737,284.70元（含税）。A股股东中，无限售流通股红利由中国结算上海分公司派发，部分股东由公司直接发放。涉及个人、QFII、沪股通等不同股东类型的税收处理方式。H股股东分红不适用本公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700000616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0183","BK0239","600332","BK1521","00874","BK0096","BK1574","09939","BK1191","BK0175","159938","BK0012","BK0196","BK1515","BK0097","BK1161","BK1197","BK0028","BK1606","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665946367","title":"议程一览｜科创出海，药启新程·2026上海国际医药健康创新与资本大会暨第15届医药CEO论坛（更新至0906）","url":"https://stock-news.laohu8.com/highlight/detail?id=2665946367","media":"国泰君安证券研究","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665946367?lang=zh_cn&edition=full","pubTime":"2026-09-06 22:14","pubTimestamp":1788704040,"startTime":"0","endTime":"0","summary":"重要提醒本订阅号所载内容仅面向国泰海通证券研究服务签约客户。因本资料暂时无法设置访问限制，根据《证券期货投资者适当性管理办法》的要求，若您并非国泰海通证券研究服务签约客户，为保证服务质量、控制投资风险，还请取消关注，请勿订阅、接收或使用本订阅号中的任何信息。法律声明本公众订阅号为国泰海通证券股份有限公司 研究所依法设立、独立运营的唯一官方订阅号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650541463&idx=1&sn=94e11f7b42b3321d7a3a0523c984bd84&chksm=89fc215ea26362c20ac5f70f33014fdf8010dec2aceca46a7aedccffcc60b30b1d2d49740242&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1574","09939","159938","BK1161","159982","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665361549","title":"迪哲医药高管发布减持计划后，股价下跌超5%！公司回应：对长期发展充满信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2665361549","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665361549?lang=zh_cn&edition=full","pubTime":"2026-09-06 14:57","pubTimestamp":1788677820,"startTime":"0","endTime":"0","summary":"迪哲医药对每经记者表示，公司始终认为，上市公司股价的长期走势根本上取决于基本面和经营实绩，并对长期发展充满信心。2026年8月至今，迪哲医药自愿披露多份利好公告。2026年9月3日盘后，迪哲医药发布了关于董事、高级管理人员减持股份计划公告。在发布高管减持计划后的首个交易日，迪哲医药股价表现不佳，盘中跌幅一度超过6%，收盘下跌5.01%。截至9月4日，迪哲医药收盘价报57.01元，市值约为265.5亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-09-06/doc-iniqwnma6518378.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-06/doc-iniqwnma6518378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","09939","BK1161","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665567365","title":"每周股票复盘：迪哲医药（688192）舒沃哲一线治疗肺癌适应症获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2665567365","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665567365?lang=zh_cn&edition=full","pubTime":"2026-09-06 01:30","pubTimestamp":1788629429,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，迪哲医药报收于57.07元，较上周的58.67元下跌2.73%。本周，迪哲医药9月3日盘中最高价报60.69元。本周关注点来自公司公告汇总：舒沃哲新增适应症上市申请获美国FDA受理，拟用于一线治疗EGFR exon20ins非小细胞肺癌。此前，舒沃哲已获中美两国突破性疗法认定，并已在中美获批用于二线及后线治疗。迪哲医药与阿斯利康签署的《许可协议》已于2026年8月31日正式生效，授权阿斯利康在全球范围内独家开发和商业化舒沃哲。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1515","09939","159938","688192","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665350111","title":"倒计时3天｜科创出海，药启新程·2026上海国际医药健康创新与资本大会暨第15届医药CEO论坛","url":"https://stock-news.laohu8.com/highlight/detail?id=2665350111","media":"国泰君安证券研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665350111?lang=zh_cn&edition=full","pubTime":"2026-09-05 06:00","pubTimestamp":1788559200,"startTime":"0","endTime":"0","summary":"重要提醒本订阅号所载内容仅面向国泰海通证券研究服务签约客户。因本资料暂时无法设置访问限制，根据《证券期货投资者适当性管理办法》的要求，若您并非国泰海通证券研究服务签约客户，为保证服务质量、控制投资风险，还请取消关注，请勿订阅、接收或使用本订阅号中的任何信息。法律声明本公众订阅号为国泰海通证券股份有限公司 研究所依法设立、独立运营的唯一官方订阅号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650541361&idx=1&sn=63ac25bea321267b67c20481daaceafa&chksm=89294a6277855c0b5576457cd3c9103e00b417dd69a0b295a7b3f49eb2aa917d359c806d4e05&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1574","09939","159938","BK1161","159982","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664332059","title":"礼邦医药-B(09637)H股获纳入港股通及恒生综合指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2664332059","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664332059?lang=zh_cn&edition=full","pubTime":"2026-09-04 21:34","pubTimestamp":1788528840,"startTime":"0","endTime":"0","summary":"H股获纳入港股通乃基于其获纳入恒生综合指数。根据恒生指数有限公司于2026 年8月21日公布的截至2026年6月30日的恒生指数系列季度检讨结果，H股获纳入恒生综合指数成份股，有关变动已于2026年9月4日(星期五)收市后实施，并将自 2026年9月7日(星期一)起生效。董事会认为，H股获纳入港股通及恒生综合指数，反映了资本市场对公司价值及长期发展前景的认可，并将有助于进一步扩大公司的投资者基础，提升H股的交易流动性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FLHK","09939","159938","09637","BK1574","BK1515","BK1191","BK1161","HSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664067330","title":"【千亿药企龙头深度拆解】序章：读懂医药龙头的定价底层逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2664067330","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664067330?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:35","pubTimestamp":1788510900,"startTime":"0","endTime":"0","summary":"理解这一底层逻辑，是有效开展港股医药投研的第一步。当前港股千亿药企格局呈现明显分化态势，不同类型企业的估值逻辑与涨跌驱动因素各不相同，这也为投资者提供了多样化的观察与配置视角。本专栏拆解的上市企业均为该榜单的核心候选，兼具行业代表性与市场影响力，亦是观察港股医药板块动态的重要参考坐标。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514105&idx=2&sn=d8ca392d4d324022cb2b4462bb9bc726&chksm=f304d4e6dbfa638c7d6757b3f5ceecdad7dcb1117ab48872a6f207ed5cbe7e1509d99613c06d&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1574","BK1515","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664369163","title":"纽欧申医药完成逾8000万美元的B轮超额融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2664369163","media":"经纬创投","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664369163?lang=zh_cn&edition=full","pubTime":"2026-09-04 12:19","pubTimestamp":1788495540,"startTime":"0","endTime":"0","summary":"综述近日，纽欧申医药宣布完成逾8000万美元的B轮超额融资，经纬创投参与投资。三大核心项目均处于临床阶段目前，纽欧申医药已构建起涵盖小分子创新药的差异化研发管线，三大核心项目均处于临床开发阶段：NS-079 · 非致幻性5-HT2A受体部分激动剂开拓难治性抑郁症新路径NS-079的核心作用机制是神经可塑性调节。目前，NS-079已在澳洲启动首次人体试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3ODk5OTEzOA==&mid=2962188653&idx=2&sn=9648168cc3abbfe551d228585ca0897a&chksm=abf451d91501b032eafed6bf17710a8b01a3f275a7235b49ed55199b530f45fcd590769d04a4&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["09939","159938","BK1574","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664388377","title":"劲方医药-B(02595)存仓市值总计19.55亿港元 股东将4373.09万股股票存入渣打银行(香港)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664388377","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664388377?lang=zh_cn&edition=full","pubTime":"2026-09-04 08:34","pubTimestamp":1788482051,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，9月3日，劲方医药-B(02595)出现存仓异动，存仓市值总计19.55亿港元，占比19.65%。该公司股东将4373.09万股股票存入渣打银行(香港)，持股比例增加12.44%。劲方医药此前发布公告，GFH375已进入一线治疗KRAS G12D突变型晚期非小细胞肺癌(NSCLC)的II期研究，包括单药疗法、联合EGFR单抗(西妥昔单抗)或联合化疗(培美曲塞)三种治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","BK1574","09939","159938","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664879974","title":"劲方医药-B(02595)9月3日斥资54.64万港元回购2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664879974","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664879974?lang=zh_cn&edition=full","pubTime":"2026-09-03 19:21","pubTimestamp":1788434461,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月3日斥资54.64万港元回购2万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491703.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1574","02595","159938","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664824858","title":"港股异动 | 同源康医药-B(02410)午后涨超9% EGFR-TKI氘申艾替尼获批一线治疗晚期非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2664824858","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664824858?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:30","pubTimestamp":1788417020,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B午后涨超9%。消息面上，同源康医药近日宣布，公司自主研发的新一代EGFR-TKI创新药甲磺酸氘申艾替尼片已正式获得中国国家药品监督管理局批准附条件上市，适应症为具有表皮生长因子受体外显子19缺失或外显子21置换突变，并伴有中枢神经系统转移的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。同源康预计收取7亿元人民币现金首付款及股份认购款，以及最高20.6亿元人民币的注册里程碑付款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","09939","BK1161","02410","KCAI","BK4585","BK1515","BK1574","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":0.1023},{"period":"1month","weight":0.0414},{"period":"3month","weight":-0.2211},{"period":"6month","weight":-0.5154},{"period":"1year","weight":-0.2046},{"period":"ytd","weight":-0.0383}],"compareEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0345},{"period":"6month","weight":-0.0188},{"period":"1year","weight":-0.0002},{"period":"ytd","weight":-0.0085}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.020286},{"month":2,"riseRate":0.666667,"avgChangeRate":0.174983},{"month":3,"riseRate":0.333333,"avgChangeRate":0.058562},{"month":4,"riseRate":0.666667,"avgChangeRate":0.374359},{"month":5,"riseRate":0.5,"avgChangeRate":0.006013},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.081543},{"month":7,"riseRate":0.571429,"avgChangeRate":0.098094},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.060443},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.09598},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.185801}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}